Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

We recently published a list of 12 Best Consistent Dividend Stocks to Buy. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best consistent ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 7.2% ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to ...

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

Shares of Merck & Co. Inc. slipped 4.81% to $87.87 Tuesday, on what proved to be an all-around favorable trading session for ...

The U.S. stock market had a mixed session on Tuesday. The Nasdaq Composite climbed nearly 80 points, or 0.5%, closing at ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...

MERCK & CO INC (MRK) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.